Related Experiment Video
Updated: Jun 6, 2026
10:20
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Pulmonary vascular disease associated with schistosomiasis
Ewa Kolosionek1, Alexi Crosby, Michael O Harhay
1University of Kent, Canterbury, CT2 7LR, UK.
Expert Review of Anti-Infective Therapy
|December 8, 2010
Summary
Schistosomiasis infection damages lung vasculature through inflammation and portal hypertension. Current treatments are ineffective, highlighting the need for new therapeutic strategies for this neglected tropical disease.
Area of Science:
- Cardiopulmonary Medicine
- Infectious Diseases
- Vascular Biology
Background:
- Schistosomiasis significantly impacts cardiopulmonary health, yet its effects on lung vasculature are poorly understood.
- Limited knowledge of Schistosoma immune responses hinders effective clinical care and drug development for schistosomiasis-related lung disease.
- Pulmonary vascular remodeling and pathophysiologic alterations are linked to egg-induced inflammation and portal hypertension in schistosomiasis.
Purpose of the Study:
- To elucidate the pathogenesis and clinical characteristics of schistosomiasis affecting lung vasculature.
- To review the current understanding of immune responses to Schistosoma and their cardiopulmonary consequences.
- To identify therapeutic challenges and opportunities for pulmonary vascular disease secondary to schistosomiasis.
Main Methods:
- Literature review focusing on pathogenesis, clinical presentation, and treatment of schistosomiasis-induced pulmonary vascular disease.
- Analysis of inflammatory and hemodynamic mechanisms contributing to pulmonary vascular remodeling.
- Evaluation of current and potential therapeutic interventions, including praziquantel and specialty drugs.
Main Results:
- Inflammatory responses to Schistosoma eggs drive pulmonary vessel remodeling.
- Portal hypertension exacerbates pathophysiologic changes in the pulmonary vascular bed.
- Praziquantel offers limited efficacy for established pulmonary hypertension; no clinical trials exist for treating schistosomiasis-related pulmonary vascular disease.
Conclusions:
- Schistosomiasis poses a significant threat to lung vasculature, necessitating further research into its pathogenesis.
- Existing treatments are inadequate, and novel therapeutic approaches are urgently required.
- Specialty drugs show promise but face significant barriers in cost, safety, and efficacy studies for endemic populations.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:18Pulmonary Edema II: Pathophysiology
Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...